α1-giardin based live heterologous vaccine protects against Giardia lamblia infection in a murine model

Gabriela Jenikova, Petr Hruz, Mattias K. Andersson, Noa Tejman-Yarden, Patricia C D Ferreira, Yolanda S. Andersen, Barbara J. Davids, Frances D. Gillin, Staffan G. Svärd, Roy Curtiss, Lars Eckmann

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Giardia lamblia is a leading protozoan cause of diarrheal disease worldwide, yet preventive medical strategies are not available. A crude veterinary vaccine has been licensed for cats and dogs, but no defined human vaccine is available. We tested the vaccine potential of three conserved antigens previously identified in human and murine giardiasis, α1-giardin, α-enolase, and ornithine carbamoyl transferase, in a murine model of G. lamblia infection. Live recombinant attenuated Salmonella enterica Serovar Typhimurium vaccine strains were constructed that stably expressed each antigen, maintained colonization capacity, and sustained total attenuation in the host. Oral administration of the vaccine strains induced antigen-specific serum IgG, particularly IgG 2A, and mucosal IgA for α1-giardin and α-enolase, but not for ornithine carbamoyl transferase. Immunization with the α1-giardin vaccine induced significant protection against subsequent G. lamblia challenge, which was further enhanced by boosting with cholera toxin or sublingual α1-giardin administration. The α-enolase vaccine afforded no protection. Analysis of α1-giardin from divergent assemblage A and B isolates of G. lamblia revealed >97% amino acid sequence conservation and immunological cross-reactivity, further supporting the potential utility of this antigen in vaccine development. Together. These results indicate that α1-giardin is a suitable candidate antigen for a vaccine against giardiasis.

Original languageEnglish (US)
Pages (from-to)9529-9537
Number of pages9
JournalVaccine
Volume29
Issue number51
DOIs
StatePublished - Nov 28 2011

Fingerprint

Giardia lamblia
Vaccines
animal models
vaccines
Infection
infection
phosphopyruvate hydratase
antigens
Phosphopyruvate Hydratase
Carboxyl and Carbamoyl Transferases
ornithine carbamoyltransferase
Antigens
giardiasis
Giardiasis
Ornithine
Immunoglobulin G
cholera toxin
vaccine development
Salmonella enterica
Cholera Toxin

Keywords

  • Animal models
  • Giardiasis
  • Live oral vaccines

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Jenikova, G., Hruz, P., Andersson, M. K., Tejman-Yarden, N., Ferreira, P. C. D., Andersen, Y. S., ... Eckmann, L. (2011). α1-giardin based live heterologous vaccine protects against Giardia lamblia infection in a murine model. Vaccine, 29(51), 9529-9537. https://doi.org/10.1016/j.vaccine.2011.09.126

α1-giardin based live heterologous vaccine protects against Giardia lamblia infection in a murine model. / Jenikova, Gabriela; Hruz, Petr; Andersson, Mattias K.; Tejman-Yarden, Noa; Ferreira, Patricia C D; Andersen, Yolanda S.; Davids, Barbara J.; Gillin, Frances D.; Svärd, Staffan G.; Curtiss, Roy; Eckmann, Lars.

In: Vaccine, Vol. 29, No. 51, 28.11.2011, p. 9529-9537.

Research output: Contribution to journalArticle

Jenikova, G, Hruz, P, Andersson, MK, Tejman-Yarden, N, Ferreira, PCD, Andersen, YS, Davids, BJ, Gillin, FD, Svärd, SG, Curtiss, R & Eckmann, L 2011, 'α1-giardin based live heterologous vaccine protects against Giardia lamblia infection in a murine model', Vaccine, vol. 29, no. 51, pp. 9529-9537. https://doi.org/10.1016/j.vaccine.2011.09.126
Jenikova G, Hruz P, Andersson MK, Tejman-Yarden N, Ferreira PCD, Andersen YS et al. α1-giardin based live heterologous vaccine protects against Giardia lamblia infection in a murine model. Vaccine. 2011 Nov 28;29(51):9529-9537. https://doi.org/10.1016/j.vaccine.2011.09.126
Jenikova, Gabriela ; Hruz, Petr ; Andersson, Mattias K. ; Tejman-Yarden, Noa ; Ferreira, Patricia C D ; Andersen, Yolanda S. ; Davids, Barbara J. ; Gillin, Frances D. ; Svärd, Staffan G. ; Curtiss, Roy ; Eckmann, Lars. / α1-giardin based live heterologous vaccine protects against Giardia lamblia infection in a murine model. In: Vaccine. 2011 ; Vol. 29, No. 51. pp. 9529-9537.
@article{204b4dbc7a3b4ea6a16abe3e610849b4,
title = "α1-giardin based live heterologous vaccine protects against Giardia lamblia infection in a murine model",
abstract = "Giardia lamblia is a leading protozoan cause of diarrheal disease worldwide, yet preventive medical strategies are not available. A crude veterinary vaccine has been licensed for cats and dogs, but no defined human vaccine is available. We tested the vaccine potential of three conserved antigens previously identified in human and murine giardiasis, α1-giardin, α-enolase, and ornithine carbamoyl transferase, in a murine model of G. lamblia infection. Live recombinant attenuated Salmonella enterica Serovar Typhimurium vaccine strains were constructed that stably expressed each antigen, maintained colonization capacity, and sustained total attenuation in the host. Oral administration of the vaccine strains induced antigen-specific serum IgG, particularly IgG 2A, and mucosal IgA for α1-giardin and α-enolase, but not for ornithine carbamoyl transferase. Immunization with the α1-giardin vaccine induced significant protection against subsequent G. lamblia challenge, which was further enhanced by boosting with cholera toxin or sublingual α1-giardin administration. The α-enolase vaccine afforded no protection. Analysis of α1-giardin from divergent assemblage A and B isolates of G. lamblia revealed >97{\%} amino acid sequence conservation and immunological cross-reactivity, further supporting the potential utility of this antigen in vaccine development. Together. These results indicate that α1-giardin is a suitable candidate antigen for a vaccine against giardiasis.",
keywords = "Animal models, Giardiasis, Live oral vaccines",
author = "Gabriela Jenikova and Petr Hruz and Andersson, {Mattias K.} and Noa Tejman-Yarden and Ferreira, {Patricia C D} and Andersen, {Yolanda S.} and Davids, {Barbara J.} and Gillin, {Frances D.} and Sv{\"a}rd, {Staffan G.} and Roy Curtiss and Lars Eckmann",
year = "2011",
month = "11",
day = "28",
doi = "10.1016/j.vaccine.2011.09.126",
language = "English (US)",
volume = "29",
pages = "9529--9537",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "51",

}

TY - JOUR

T1 - α1-giardin based live heterologous vaccine protects against Giardia lamblia infection in a murine model

AU - Jenikova, Gabriela

AU - Hruz, Petr

AU - Andersson, Mattias K.

AU - Tejman-Yarden, Noa

AU - Ferreira, Patricia C D

AU - Andersen, Yolanda S.

AU - Davids, Barbara J.

AU - Gillin, Frances D.

AU - Svärd, Staffan G.

AU - Curtiss, Roy

AU - Eckmann, Lars

PY - 2011/11/28

Y1 - 2011/11/28

N2 - Giardia lamblia is a leading protozoan cause of diarrheal disease worldwide, yet preventive medical strategies are not available. A crude veterinary vaccine has been licensed for cats and dogs, but no defined human vaccine is available. We tested the vaccine potential of three conserved antigens previously identified in human and murine giardiasis, α1-giardin, α-enolase, and ornithine carbamoyl transferase, in a murine model of G. lamblia infection. Live recombinant attenuated Salmonella enterica Serovar Typhimurium vaccine strains were constructed that stably expressed each antigen, maintained colonization capacity, and sustained total attenuation in the host. Oral administration of the vaccine strains induced antigen-specific serum IgG, particularly IgG 2A, and mucosal IgA for α1-giardin and α-enolase, but not for ornithine carbamoyl transferase. Immunization with the α1-giardin vaccine induced significant protection against subsequent G. lamblia challenge, which was further enhanced by boosting with cholera toxin or sublingual α1-giardin administration. The α-enolase vaccine afforded no protection. Analysis of α1-giardin from divergent assemblage A and B isolates of G. lamblia revealed >97% amino acid sequence conservation and immunological cross-reactivity, further supporting the potential utility of this antigen in vaccine development. Together. These results indicate that α1-giardin is a suitable candidate antigen for a vaccine against giardiasis.

AB - Giardia lamblia is a leading protozoan cause of diarrheal disease worldwide, yet preventive medical strategies are not available. A crude veterinary vaccine has been licensed for cats and dogs, but no defined human vaccine is available. We tested the vaccine potential of three conserved antigens previously identified in human and murine giardiasis, α1-giardin, α-enolase, and ornithine carbamoyl transferase, in a murine model of G. lamblia infection. Live recombinant attenuated Salmonella enterica Serovar Typhimurium vaccine strains were constructed that stably expressed each antigen, maintained colonization capacity, and sustained total attenuation in the host. Oral administration of the vaccine strains induced antigen-specific serum IgG, particularly IgG 2A, and mucosal IgA for α1-giardin and α-enolase, but not for ornithine carbamoyl transferase. Immunization with the α1-giardin vaccine induced significant protection against subsequent G. lamblia challenge, which was further enhanced by boosting with cholera toxin or sublingual α1-giardin administration. The α-enolase vaccine afforded no protection. Analysis of α1-giardin from divergent assemblage A and B isolates of G. lamblia revealed >97% amino acid sequence conservation and immunological cross-reactivity, further supporting the potential utility of this antigen in vaccine development. Together. These results indicate that α1-giardin is a suitable candidate antigen for a vaccine against giardiasis.

KW - Animal models

KW - Giardiasis

KW - Live oral vaccines

UR - http://www.scopus.com/inward/record.url?scp=81955164754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81955164754&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.09.126

DO - 10.1016/j.vaccine.2011.09.126

M3 - Article

VL - 29

SP - 9529

EP - 9537

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 51

ER -